Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.

Cost-utility analysis Guidelines Health technology assessment Multi-attribute utility instruments Pharmacoeconomics Utility

Journal

The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 06 09 2019
accepted: 25 04 2020
pubmed: 10 6 2020
medline: 11 9 2021
entrez: 10 6 2020
Statut: ppublish

Résumé

Several multi-attribute utility instruments (MAUIs) are available from which utilities can be derived for use in cost-utility analysis (CUA). This study provides a review of recommendations from national health technology assessment (HTA) agencies regarding the choice of MAUIs. A list was compiled of HTA agencies that provide or refer to published official pharmacoeconomic (PE) guidelines for pricing, reimbursement or market access. The guidelines were reviewed for recommendations on the indirect calculation of utilities and categorized as: a preference for a specific MAUI; providing no MAUI preference, but providing examples of suitable MAUIs and/or recommending the use of national value sets; and recommending CUA, but not providing examples of MAUIs. Thirty-four PE guidelines were included for review. MAUIs named for use in CUA: EQ-5D (n = 29 guidelines), the SF-6D (n = 11), HUI (n = 10), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). EQ-5D was a preferred MAUI in 15 guidelines. Alongside the EQ-5D, the HUI was a preferred MAUI in one guideline, with DALY disability weights mentioned in another. Fourteen guidelines expressed no preference for a specific MAUI, but provided examples: EQ-5D (n = 14), SF-6D (n = 11), HUI (n = 9), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). Of those that did not specify a particular MAUI, 12 preferred calculating utilities using national preference weights. The EQ-5D, HUI, and SF-6D were the three MAUIs most frequently mentioned in guidelines. The most commonly cited MAUI (in 85% of PE guidelines) was EQ-5D, either as a preferred MAUI or as an example of a suitable MAUI for use in CUA in HTA.

Sections du résumé

BACKGROUND BACKGROUND
Several multi-attribute utility instruments (MAUIs) are available from which utilities can be derived for use in cost-utility analysis (CUA). This study provides a review of recommendations from national health technology assessment (HTA) agencies regarding the choice of MAUIs.
METHODS METHODS
A list was compiled of HTA agencies that provide or refer to published official pharmacoeconomic (PE) guidelines for pricing, reimbursement or market access. The guidelines were reviewed for recommendations on the indirect calculation of utilities and categorized as: a preference for a specific MAUI; providing no MAUI preference, but providing examples of suitable MAUIs and/or recommending the use of national value sets; and recommending CUA, but not providing examples of MAUIs.
RESULTS RESULTS
Thirty-four PE guidelines were included for review. MAUIs named for use in CUA: EQ-5D (n = 29 guidelines), the SF-6D (n = 11), HUI (n = 10), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). EQ-5D was a preferred MAUI in 15 guidelines. Alongside the EQ-5D, the HUI was a preferred MAUI in one guideline, with DALY disability weights mentioned in another. Fourteen guidelines expressed no preference for a specific MAUI, but provided examples: EQ-5D (n = 14), SF-6D (n = 11), HUI (n = 9), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). Of those that did not specify a particular MAUI, 12 preferred calculating utilities using national preference weights.
CONCLUSIONS CONCLUSIONS
The EQ-5D, HUI, and SF-6D were the three MAUIs most frequently mentioned in guidelines. The most commonly cited MAUI (in 85% of PE guidelines) was EQ-5D, either as a preferred MAUI or as an example of a suitable MAUI for use in CUA in HTA.

Identifiants

pubmed: 32514643
doi: 10.1007/s10198-020-01195-8
pii: 10.1007/s10198-020-01195-8
pmc: PMC7561556
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1245-1257

Références

Pharmacoeconomics. 2017 Dec;35(Suppl 1):11-19
pubmed: 29052162
Pharmacoeconomics. 2010;28(10):831-8
pubmed: 20831290
Pharmacoeconomics. 2013 Apr;31(4):257-67
pubmed: 23322587
Value Health Reg Issues. 2017 Dec;14:20-27
pubmed: 29254537
Eur J Health Econ. 2014 May;15 Suppl 1:S13-25
pubmed: 24832832
Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):551-558
pubmed: 29958008
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
Health Econ. 2016 Feb;25 Suppl 1:179-92
pubmed: 26763688
Qual Life Res. 2016 Nov;25(11):2693-2710
pubmed: 27472992
Pharmacoeconomics. 2009;27(11):891-901
pubmed: 19888790
Front Med (Lausanne). 2019 Nov 29;6:278
pubmed: 31850356
Qual Life Res. 2015 Aug;24(8):2045-53
pubmed: 25636660
J Med Econ. 2018 Jan;21(1):85-96
pubmed: 28959910

Auteurs

Matthew Kennedy-Martin (M)

Kennedy Martin Health Outcomes Ltd, Suite 404, The Dock Hub, Wilbury Villas, Hove, BN3 6AH, UK. matt@kmho.co.uk.

Bernhard Slaap (B)

Department of Psychiatry, Section of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands.
EuroQol Research Foundation, Rotterdam, The Netherlands.

Michael Herdman (M)

Office of Health Economics (OHE), London, UK.

Mandy van Reenen (M)

EuroQol Research Foundation, Rotterdam, The Netherlands.

Tessa Kennedy-Martin (T)

Kennedy Martin Health Outcomes Ltd, Suite 404, The Dock Hub, Wilbury Villas, Hove, BN3 6AH, UK.

Wolfgang Greiner (W)

Department of Health Economics at the School of Public Health, Bielefeld University, Bielefeld, Germany.

Jan Busschbach (J)

Department of Psychiatry, Section of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands.

Kristina S Boye (KS)

Eli Lilly and Company, Indianapolis, IN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH